Dr. Reckamp on Current Heat Shock Protein Clinical Trials

Dr. Karen Reckamp City of Hope cancer center on Current Heat Shock Protein Clinical Trials

Karen Reckamp, MD, MS, assistant professor, Department of Medical Oncology & Therapeutics Research, City of Hope, Duarte, California, describes the various clinical studies currently underway examining the use of heat shock proteins.

Clinical trials are currently looking specifically at ALK translocated, crizotinib resistance, and patient that have not yet received crizotinib. Further examination is being completed into heat shock proteins in combination with docetaxel and other targets and biomarkers that specify which patients will have the most benefit.